drugset / Trial / NCT03965494
AXL Inhibitor BGB324 in Treating Participants With Recurrent Glioblastoma Undergoing Surgery
Phase 0
Terminated
10 enrolled
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
BerGenBio ASA · collabNational Cancer Institute (NCI) · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
This phase I trial studies how well AXL inhibitor BGB324 works in treating participants with glioblastoma that has come back who are undergoing surgery. AXL inhibitor BGB324 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Timeline
- Start
- 2020-01-02
- Primary completion
- 2023-10-31
- Completion
- 2023-10-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bemcentinib | Small molecule | — | Oral |